tradingkey.logo

CVRx Inc

CVRX
查看詳細走勢圖
6.550USD
-0.090-1.36%
收盤 02/06, 16:00美東報價延遲15分鐘
171.57M總市值
虧損本益比TTM

CVRx Inc

6.550
-0.090-1.36%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.36%

5天

-4.38%

1月

-17.30%

6月

-7.22%

今年開始到現在

-7.75%

1年

-55.47%

查看詳細走勢圖

TradingKey CVRx Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

CVRx Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名77/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為11.50。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

CVRx Inc評分

相關信息

行業排名
77 / 205
全市場排名
211 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

CVRx Inc亮點

亮點風險
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
業績高增長
公司營業收入穩步增長,連續3年增長128.28%
業績增長期
公司處於發展階段,最新年度總收入51.29M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入51.29M美元
估值高估
公司最新PE估值-3.29,處於3年歷史高位
機構減倉
最新機構持股17.05M股,環比減少0.31%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉1.65K股

分析師目標

基於 7 分析師
買入
評級
11.500
目標均價
+73.19%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

CVRx Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

CVRx Inc簡介

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
公司代碼CVRX
公司CVRx Inc
CEOHykes (Kevin)
網址https://www.cvrx.com/
KeyAI